A pill called daraxonrasib is being hailed by experts as a "game-changer" drug after it was found to have doubled the survival rate in pancreatic cancer patients. A trial found that patients who took the drug lived longer (13.2 months) compared to patients who were on chemotherapy (6.6-6.7 months). The data was presented by the American Society of Clinical Oncology.